About Cajal Neuroscience
Cajal Neuroscience is a company based in Seattle (United States) founded in 2020 by Ian Peikon and Andrew Dervan. Cajal Neuroscience has raised $96 million across 1 funding round from investors including Evotec, ARE and Bristol-Myers Squibb. Cajal Neuroscience offers products and services including Drug Discovery Platform and Therapeutics Development Services. Cajal Neuroscience operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Seattle, United States
- Founders Ian Peikon, Andrew Dervan
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cajal Neuroscience Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$96 M (USD)
in 1 rounds
-
Latest Funding Round
$96 M (USD), Series A
Nov 29, 2022
-
Investors
Evotec
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cajal Neuroscience
Cajal Neuroscience offers a comprehensive portfolio of products and services, including Drug Discovery Platform and Therapeutics Development Services.
Platform for identifying drug targets in neurodegenerative diseases using advanced analyses
Services to develop potential treatments for neurodegenerative conditions
People of Cajal Neuroscience
Unlock access to complete
Unlock access to complete
Funding Insights of Cajal Neuroscience
Cajal Neuroscience has successfully raised a total of $96M through 1 strategic funding round. The most recent funding activity was a Series A round of $96 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cajal Neuroscience
Cajal Neuroscience has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Evotec, ARE and Bristol-Myers Squibb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early-stage technology companies are funded by Lux Capital.
|
Locked | Locked | Locked | |
|
Early-stage investments in US life science startups are focused on.
|
Locked | Locked | Locked | |
|
Early-stage investments in tech sectors are managed by the firm.
|
Locked | Locked | Locked |
Investor details for Cajal Neuroscience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cajal Neuroscience
Investment portfolio details for Cajal Neuroscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cajal Neuroscience
Detailed financials for Cajal Neuroscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cajal Neuroscience Comparisons
Peer comparison for Cajal Neuroscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cajal Neuroscience
Cajal Neuroscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Cajal Neuroscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cajal Neuroscience
Complete news archive for Cajal Neuroscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cajal Neuroscience
Cajal Neuroscience was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Cajal Neuroscience is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Cajal Neuroscience is a funded company, having raised a total of $96M across 1 funding round to date.
Cajal Neuroscience was founded in 2020 in Seattle, United States, within the biotechnology sector focused on neurodegenerative diseases. Viral tools and platforms are developed to screen targets with functional impacts on disease progression. Functional genetic screening and multi-omics approaches are utilized to advance precision medicine solutions for these conditions. Operations emphasize target identification and drug development based on genetic insights.
Cajal Neuroscience's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Cajal Neuroscience offers Drug Discovery Platform and Therapeutics Development Services.
Cajal Neuroscience has 7 investors. Key investors include Evotec, ARE, Bristol-Myers Squibb, The Column Group, and Lux Capital.